Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile

IF 5.7 2区医学 Q1 NEUROSCIENCES

Biological Psychiatry-Cognitive Neuroscience and Neuroimaging Pub Date : 2024-05-01 DOI:10.1016/j.bpsc.2024.01.007

Friederike Holze , Nirmal Singh , Matthias E. Liechti , Deepak Cyril D’Souza

{"title":"Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile","authors":"Friederike Holze , Nirmal Singh , Matthias E. Liechti , Deepak Cyril D’Souza","doi":"10.1016/j.bpsc.2024.01.007","DOIUrl":null,"url":null,"abstract":"<div><p>Psychedelic compounds, including psilocybin, LSD (lysergic acid diethylamide), DMT (<em>N,N</em> -dimethyltryptamine), and 5-MeO-DMT (5-methoxy-<em>N,N</em>-dimethyltryptamine), all of which are serotonin 2A receptor agonists, are being investigated as potential treatments. This review aims to summarize the current clinical research on these 4 compounds and mescaline to guide future research. Their mechanism(s) of action, pharmacokinetics, pharmacodynamics, efficacy, and safety were reviewed. While evidence for therapeutic indications, with the exception of psilocybin for depression, is still relatively scarce, we noted no differences in psychedelic effects beyond effect duration. Therefore, it remains unclear whether different receptor profiles contribute to the therapeutic potential of these compounds. More research is needed to differentiate these compounds in order to inform which compounds might be best for different therapeutic uses.</p></div>","PeriodicalId":54231,"journal":{"name":"Biological Psychiatry-Cognitive Neuroscience and Neuroimaging","volume":"9 5","pages":"Pages 472-489"},"PeriodicalIF":5.7000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S245190222400020X/pdfft?md5=d8cb42b128106b74964a069246315b36&pid=1-s2.0-S245190222400020X-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biological Psychiatry-Cognitive Neuroscience and Neuroimaging","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S245190222400020X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Psychedelic compounds, including psilocybin, LSD (lysergic acid diethylamide), DMT (N,N -dimethyltryptamine), and 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine), all of which are serotonin 2A receptor agonists, are being investigated as potential treatments. This review aims to summarize the current clinical research on these 4 compounds and mescaline to guide future research. Their mechanism(s) of action, pharmacokinetics, pharmacodynamics, efficacy, and safety were reviewed. While evidence for therapeutic indications, with the exception of psilocybin for depression, is still relatively scarce, we noted no differences in psychedelic effects beyond effect duration. Therefore, it remains unclear whether different receptor profiles contribute to the therapeutic potential of these compounds. More research is needed to differentiate these compounds in order to inform which compounds might be best for different therapeutic uses.

查看原文本刊更多论文

Serotonergic Psychedelics - a Comparative Review Comparing the Efficacy, Safety, Pharmacokinetics and Binding Profile of Serotonergic Psychedelics.

迷幻化合物，包括迷幻药、迷幻剂、DMT 和 5-MeO-DMT，都是血清素（5-HT）2A 受体激动剂，目前正被研究作为潜在的治疗方法。本综述旨在总结目前有关这四种化合物和麦司卡林的临床研究，为今后的研究提供指导。综述了它们的作用机制、药代动力学、药效学、疗效和安全性。虽然除了治疗抑郁症的银环蛇毒素外，治疗适应症的证据仍然相对较少，但我们注意到，除了作用持续时间外，迷幻药的效果并无差异。因此，目前还不清楚不同的受体特征是否有助于发挥这些化合物的治疗潜力。需要进行更多的研究来区分这些化合物，以便了解哪些化合物最适合不同的治疗用途。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biological Psychiatry-Cognitive Neuroscience and Neuroimaging Neuroscience-Biological Psychiatry

CiteScore

10.40

自引率

1.70%

发文量

247

审稿时长

30 days

期刊介绍： Biological Psychiatry: Cognitive Neuroscience and Neuroimaging is an official journal of the Society for Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms, and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal focuses on studies using the tools and constructs of cognitive neuroscience, including the full range of non-invasive neuroimaging and human extra- and intracranial physiological recording methodologies. It publishes both basic and clinical studies, including those that incorporate genetic data, pharmacological challenges, and computational modeling approaches. The journal publishes novel results of original research which represent an important new lead or significant impact on the field. Reviews and commentaries that focus on topics of current research and interest are also encouraged.